C David Sjostrom
Overview
Explore the profile of C David Sjostrom including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
61
Citations
5617
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
van Mil D, Vart P, Chertow G, Gansevoort R, Rossing P, Toto R, et al.
Clin J Am Soc Nephrol
. 2024 Oct;
19(12):1574-1584.
PMID: 39475817
No abstract available.
2.
Kitzman D, Voors A, Mentz R, Lewis G, Perl S, Myte R, et al.
JAMA Cardiol
. 2024 Aug;
9(10):892-900.
PMID: 39141378
Importance: Elevated serum uric acid (SUA) level may contribute to endothelial dysfunction; therefore, SUA is an attractive target for heart failure with preserved ejection fraction (HFpEF). However, to the authors'...
3.
McEwan P, Gabb P, Davis J, Garcia Sanchez J, Sjostrom C, Barone S, et al.
Nephrol Dial Transplant
. 2024 May;
39(12):2040-2047.
PMID: 38730538
Background: Chronic kidney disease (CKD) presents a significant clinical and economic burden to healthcare systems worldwide, which increases considerably with progression towards kidney failure. The Dapagliflozin and Prevention of Adverse...
4.
Heerspink H, Stack A, Terkeltaub R, Jongs N, Inker L, Bjursell M, et al.
J Am Soc Nephrol
. 2024 Apr;
35(5):594-606.
PMID: 38564654
No abstract available.
5.
Regan J, Mentz R, Nguyen M, Green J, Truby L, Ilkayeva O, et al.
JCI Insight
. 2023 Aug;
8(17).
PMID: 37552540
Metabolic mechanisms underlying the heterogeneity of major adverse cardiovascular (CV) event (MACE) risk in individuals with type 2 diabetes mellitus (T2D) remain unclear. We hypothesized that circulating metabolites reflecting mitochondrial...
6.
Chertow G, Correa-Rotter R, Vart P, Jongs N, McMurray J, Rossing P, et al.
J Am Heart Assoc
. 2023 Apr;
12(9):e028739.
PMID: 37119064
Background The DAPA-CKD (Dapagliflozin and Prevention of Adverse Outcomes in Chronic Kidney Disease) trial (NCT03036150) demonstrated that dapagliflozin reduced the risk of kidney and cardiovascular events in patients with chronic...
7.
Iqbal N, Ambery P, Logue J, Mallappa A, Sjostrom C
Diabetes Res Clin Pract
. 2023 Apr;
199:110669.
PMID: 37075928
Treatment of people with type 2 diabetes mellitus (T2D) and obesity should include glycemic control and sustained weight loss. However, organ protection and/or risk reduction for co-morbidities have also emerged...
8.
van der Aart-van der Beek A, Apperloo E, Jongs N, Rouw D, Sjostrom C, Friedli I, et al.
Diabetes Obes Metab
. 2023 Feb;
25(6):1758-1768.
PMID: 36843215
Aim: To evaluate the albuminuria-lowering effect of dapagliflozin, exenatide, and the combination of dapagliflozin and exenatide in patients with type 2 diabetes and microalbuminuria or macroalbuminuria. Methods: Participants with type...
9.
Beernink J, Persson F, Jongs N, Laverman G, Chertow G, McMurray J, et al.
Diabetes Care
. 2023 Jan;
46(3):602-607.
PMID: 36662635
Objective: To determine whether the benefits of dapagliflozin in patients with type 2 diabetes and chronic kidney disease (CKD) in the Dapagliflozin And Prevention of Adverse Outcomes in CKD trial...
10.
Schechter M, Jongs N, Chertow G, Mosenzon O, McMurray J, Correa-Rotter R, et al.
Ann Intern Med
. 2022 Dec;
176(1):59-66.
PMID: 36469914
Background: Acute hospitalizations are common in patients with chronic kidney disease (CKD) and often lead to decreases in health-related quality of life and increased care costs. Objective: To determine the...